- The European Commission approves Biogen Idec's (BIIB +11.2%) Plegridy (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS). It is the only pegylated interferon approved for RRMS.
- Patients dose themselves every two weeks with a subcutaneous injection using a prefilled syringe.
- Plegridy is Biogen's fifth product offering for MS.
From other sites
Video at CNBC.com (Jul 24, 2015)
Video at CNBC.com (Jul 22, 2015)
at CNBC.com (Mar 23, 2015)
Video at CNBC.com (Mar 23, 2015)
at CNBC.com (Mar 20, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs